BACKGROUND AND OBJECTIVES: Dendritic cells (DC) play a critical role in the regulation of alloimmune responses and might influence the outcome of allogeneic stem cell transplantation (allo-SCT). We studied the clinical relevance of early reconstitution of DC after reduced-intensity conditioning allo-SCT (allo-RIC). DESIGN AND METHODS: This study included 79 adult patients undergoing allo-RIC from HLA-identical siblings. Peripheral blood samples were drawn from patients at 1 month (+1m) and 3 months (+3m) after the transplant. DC were identified as positive for HLA-DR and negative for CD3, CD19, CD14 and CD56. The expression of CD33, CD123 and CD16 was used to identify myeloid DC, plasmacytoid DC and CD16(+) DC subpopulations, respectively. RESULTS: Patients whose DC count at +1m was lower than the median had a higher probability of treatment-related mortality (TRM) (60% vs 12%; p=0.02), poorer overall survival (OS) (15% vs 45%; p=0.002) and worse event-free survival (EFS) (20% vs 38%; p=0.03). A multivariate analysis confirmed that low DC counts had a detrimental effect on OS (RR 3.2; p=0.007), relapse (RR 4.1; p=0.01), and EFS (RR 6; p=0.001). Low CD16(+) DC counts were observed to have a detrimental effect on EFS, which was due to both a higher incidence of deaths caused by infections (50% vs 0%, p=0.05) and a higher incidence of relapse (57% vs 50%; p=0.03). Indeed, the number of CD16(+) DC at +3 m was the most important prognostic factor for EFS (RR 6; p=0.001). Interpretations and Conclusions This study shows the clinical importance of DC recovery, especially of the CD16(+) DC subset, in the outcome of patients treated with allo-RIC.
BACKGROUND AND OBJECTIVES: Dendritic cells (DC) play a critical role in the regulation of alloimmune responses and might influence the outcome of allogeneic stem cell transplantation (allo-SCT). We studied the clinical relevance of early reconstitution of DC after reduced-intensity conditioning allo-SCT (allo-RIC). DESIGN AND METHODS: This study included 79 adult patients undergoing allo-RIC from HLA-identical siblings. Peripheral blood samples were drawn from patients at 1 month (+1m) and 3 months (+3m) after the transplant. DC were identified as positive for HLA-DR and negative for CD3, CD19, CD14 and CD56. The expression of CD33, CD123 and CD16 was used to identify myeloid DC, plasmacytoid DC and CD16(+) DC subpopulations, respectively. RESULTS:Patients whose DC count at +1m was lower than the median had a higher probability of treatment-related mortality (TRM) (60% vs 12%; p=0.02), poorer overall survival (OS) (15% vs 45%; p=0.002) and worse event-free survival (EFS) (20% vs 38%; p=0.03). A multivariate analysis confirmed that low DC counts had a detrimental effect on OS (RR 3.2; p=0.007), relapse (RR 4.1; p=0.01), and EFS (RR 6; p=0.001). Low CD16(+) DC counts were observed to have a detrimental effect on EFS, which was due to both a higher incidence of deaths caused by infections (50% vs 0%, p=0.05) and a higher incidence of relapse (57% vs 50%; p=0.03). Indeed, the number of CD16(+) DC at +3 m was the most important prognostic factor for EFS (RR 6; p=0.001). Interpretations and Conclusions This study shows the clinical importance of DC recovery, especially of the CD16(+) DC subset, in the outcome of patients treated with allo-RIC.
Authors: E Mimiola; O Marini; O Perbellini; A Micheletti; W Vermi; S Lonardi; C Costantini; E Meneghelli; A Andreini; C Bonetto; A Vassanelli; M Cantini; E Zoratti; D Massi; A Zamo'; A Leso; G Quaresmini; F Benedetti; G Pizzolo; M A Cassatella; C Tecchio Journal: Clin Exp Immunol Date: 2014-10 Impact factor: 4.330
Authors: M C Elze; O Ciocarlie; A Heinze; S Kloess; T Gardlowski; R Esser; T Klingebiel; P Bader; S Huenecke; M Serban; U Köhl; J L Hutton Journal: Bone Marrow Transplant Date: 2014-11-10 Impact factor: 5.483
Authors: Khalid Ali Nasif; Awad S Al Samghan; Nahla El-Sharkawy; Amr M Abass; Ebtesam Elgezawy; Safaa A A Khaled; Mahmoud I Elbadry; Marwa M Thabet Journal: J Inflamm Res Date: 2022-06-30
Authors: Julia K Bialek-Waldmann; Sabine Domning; Ruth Esser; Wolfgang Glienke; Mira Mertens; Krasimira Aleksandrova; Lubomir Arseniev; Suresh Kumar; Andreas Schneider; Johannes Koenig; Sebastian J Theobald; Hsin-Chieh Tsay; Angela D A Cornelius; Agnes Bonifacius; Britta Eiz-Vesper; Constanca Figueiredo; Dirk Schaudien; Steven R Talbot; Andre Bleich; Loukia M Spineli; Constantin von Kaisenberg; Caren Clark; Rainer Blasczyk; Michael Heuser; Arnold Ganser; Ulrike Köhl; Farzin Farzaneh; Renata Stripecke Journal: Mol Ther Methods Clin Dev Date: 2021-04-09 Impact factor: 6.698